STV analysis for fetal monitoring in severe early FGR
Official title: Short Term Variation Analysis Versus Visual Evaluation of Cardiotocography in Fetal Growth Restriction
Run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · NCT06010238 · Data updated 2026-11-12
Researchers are testing whether short-term variation (STV) analysis of fetal monitoring helps improve perinatal survival for pregnant people with severe early fetal growth restriction compared with traditional visual CTG interpretation.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 99 Years |
| Sex | Women only |
| Enrollment | 800 (estimated) |
| Sponsor | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Academic / other |
| Locations | 6 sites (Groningen, Provincie Groningen and 5 other locations) |
| Status | Recruiting |
| Started | June 18, 2025 |
| Main results expected | January 1, 2027 |
| Study ends | January 1, 2029 |
| Registry record updated | November 4, 2026 |
| Trial ID | NCT06010238 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Pregnant individuals with singleton pregnancies between 24+0 and 31+6 weeks with severe, early-onset FGR admitted for fetal monitoring.
✕Probably not a fit
Patients whose fetus does not exhibit STV-detectable differences or whose delivery timing is dictated by non-CTG clinical factors may see no benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a stepped wedge cluster randomized trial in pregnant women with severe, early-onset fetal growth restriction (before 32 weeks). It compares STV-analysis based CTG monitoring to standard visual interpretation of cardiotocography. The intervention aims to reduce fetal hypoxia-related complications by providing a potentially more reliable signal of fetal well-being. The study uses a cluster-randomized design across participating hospitals to gradually switch from standard care to STV-assisted monitoring. Enrollment targets are singletons aged 18 and older, with specific biometric or Doppler criteria defining FGR, and excluding cases with known anomalies or imminent delivery within 48 hours.
Why it matters
Potential benefit: If successful, STV analysis could improve perinatal survival and reduce hypoxia-related injuries by guiding delivery timing more accurately.
How similar studies have gone: Previous studies in CTG monitoring have shown promise for enhanced interpretation with automated analysis, but results vary and broader validation is ongoing.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Pregnant women with a singleton pregnancy between 24 weeks and 0 days and 31 weeks and 6 days with severe, early-onset fetal growth restriction, admitted in hospital or frequently evaluated ambulatory by CTG (according to local protocol) for fetal monitoring. * Fetal growth restriction is defined in line with the international Delphi consensus as biometric ultrasound measurement of the abdominal circumference (AC) OR a combination of measurements resulting in an estimated fetal weight (EFW) below the 3rd percentile (\<p3) OR a combination of EFW \<p10 AND uterine artery pulsatility index (PI) \>p95 OR umbilical artery Doppler PI \>p95. * Maternal age ≥ 18 years. * Able to provide written informed consent for collection and use of data on informed consent form in available language. Exclusion Criteria: * Known congenital or chromosomal anomalies influencing perinatal outcome. * Imminent labour or expected maternal indication for delivery \< 48 hours.
Where it's running
-
University Medical Center Groningen
Groningen, Provincie Groningen, Netherlands Recruiting -
Amsterdam University Medical Center
Amsterdam, Netherlands Not yet recruiting -
Maastricht University Medical Center+
Maastricht, Netherlands Not yet recruiting -
Radboud University Medical Center
Nijmegen, Netherlands Not yet recruiting -
Erasmus MC University Medical Center
Rotterdam, Netherlands Not yet recruiting -
Isala
Zwolle, Netherlands Not yet recruiting
Study contacts
- Principal investigator: Wessel Ganzevoort, MD PhD — Amsterdam UMC
- Study coordinator: Wessel Ganzevoort, MD PhD
- Email: j.w.ganzevoort@amsterdamumc.nl
- Phone: 003120-5669111
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Preeclampsia Biomarker Test in African Women
This study tests whether measuring the sFlt-1/PlGF ratio using quick clinic tests helps predict which pregnant women in Africa will develop severe preeclampsia.
-
New sensor for monitoring fetal health during late pregnancy
This study is testing a new non-adhesive sensor to see if it can accurately monitor the heart rates of pregnant women and their babies during late pregnancy.
-
Investigation of selective fetal growth restriction in monochorionic twins
This study is trying to find better ways to understand and manage growth problems in one twin of monochorionic twins during pregnancy, while also checking how these issues affect the twins' development later on.
-
Using melatonin to protect the brain in pregnancies with fetal growth restriction
This study is testing if giving melatonin to pregnant women with severe fetal growth restriction can help improve their baby's health and protect against brain injury before birth.
-
Maternal supplementation to improve fetal brain development in growth-restricted pregnancies
This study is testing if giving pregnant women supplements to help their babies' brain development can improve outcomes for babies who are not growing well in the womb.
-
Using ultrasound to improve detection of fetal growth issues
This study is trying to see if using ultrasound in a structured way can help doctors better spot babies that are not growing properly during pregnancy to reduce the risk of stillbirth.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.